175 related articles for article (PubMed ID: 32526706)
1. ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L.
Liu H; Guo D; Sha Y; Zhang C; Jiang Y; Hong L; Zhang J; Jiang Y; Lu L; Huang H
Aging (Albany NY); 2020 Jun; 12(11):11100-11115. PubMed ID: 32526706
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
4. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
5. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells.
Kacı FN; Kiraz Y; Çekdemir D; Baran Y
Arch Med Res; 2020 Apr; 51(3):187-193. PubMed ID: 32111493
[TBL] [Abstract][Full Text] [Related]
7. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
[TBL] [Abstract][Full Text] [Related]
8. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
9. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
10. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M
Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693
[TBL] [Abstract][Full Text] [Related]
11. Lactate Decreases Bortezomib Sensitivity and Predicts Poor Clinical Outcomes of Multiple Myeloma.
Ma NY; Li Q; Li XL; Zeng YJ; Huang DZ; Duan YS; Xia J; Liu BD; Rao LY; Rao J; Zhang X
Curr Med Sci; 2023 Aug; 43(4):679-688. PubMed ID: 37326888
[TBL] [Abstract][Full Text] [Related]
12. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
[TBL] [Abstract][Full Text] [Related]
13. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
Xu P; Jiang YF; Wang JH
Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
[TBL] [Abstract][Full Text] [Related]
14. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
15. [Study of the effects
Tian Y; Li LH; Yang GZ; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):976-981. PubMed ID: 27995884
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
Lin L; Chen D; Xiang ZF; Pei RZ; Zhang PS; Liu XH; Du XH; Lu Y
Cancer Biomark; 2017 Aug; 20(2):217-224. PubMed ID: 28869453
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of DEAD-box helicase 21 (DDX21) inhibits proliferation, cell cycle, and tumor growth in colorectal cancer via targeting cell division cycle 5-like (CDC5L).
Wang K; Li B; Fan P; Ren X; Jiang H
Bioengineered; 2021 Dec; 12(2):12647-12658. PubMed ID: 34903139
[TBL] [Abstract][Full Text] [Related]
18. Role of RACK1 on cell proliferation, adhesion, and bortezomib-induced apoptosis in multiple myeloma.
Zhang L; Xu Y; Wang L; Liu H
Int J Biol Macromol; 2019 Jan; 121():1077-1085. PubMed ID: 30315883
[TBL] [Abstract][Full Text] [Related]
19. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.
Ramakrishnan V; Mager DE
J Pharmacol Exp Ther; 2018 Jun; 365(3):734-751. PubMed ID: 29632237
[TBL] [Abstract][Full Text] [Related]
20. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]